Morgan Stanley’s Creative Medical Technology CELZ Stock Holding History

Morgan Stanley’s Portfolio CELZ Stock Details CELZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$745	Sell	514 -20	-4%	-$43	﹤0.01%	7550
2026 Q1	$1.1K	Buy	534 +500	+1,471%	+$978	﹤0.01%	7419
2025 Q4	$67	Hold	34	–	–	﹤0.01%	7768
2025 Q3	$113	Buy	34 +14	+70%	+$43	﹤0.01%	7667
2025 Q2	$53	Hold	20	–	–	﹤0.01%	7761
2025 Q1	$43	Hold	20	–	–	﹤0.01%	7765
2024 Q4	$46	Hold	20	–	–	﹤0.01%	7634
2024 Q3	$62	Hold	20	–	–	﹤0.01%	7518
2024 Q2	$77	Hold	20	–	–	﹤0.01%	7398
2024 Q1	$104	Hold	20	–	–	﹤0.01%	7371
2023 Q4	$92	Hold	20	–	–	﹤0.01%	7352
2023 Q3	$98	Hold	20	–	–	﹤0.01%	7444
2023 Q2	$93	Hold	20	–	–	﹤0.01%	7502
2023 Q1	$100	Hold	20	–	–	﹤0.01%	7572
2022 Q4	$76	Buy	+20	New	+$82	﹤0.01%	7712

Other funds holding CELZ

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's CELZ Position: Q2 2026 in Review

Morgan Stanley reduced its Creative Medical Technology (CELZ) stake by 3.7% in Q2 2026, selling an estimated $43 and leaving 514 shares worth $745. The position accounts for ﹤0.01% of the portfolio, ranked #7550.

Morgan Stanley first reported a position in CELZ in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.1K in Q1 2026. 15 funds tracked by Wall St. Rank hold CELZ as of Q2 2026.

Morgan Stanley held 514 shares of Creative Medical Technology worth $745 as of Q2 2026.
Morgan Stanley sold 20 Creative Medical Technology shares in Q2 2026, an estimated $43.
Creative Medical Technology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7550 holding.
Morgan Stanley first reported a position in Creative Medical Technology in Q4 2022 and has held it in 15 quarters since.
Morgan Stanley's Creative Medical Technology position peaked at $1.1K in Q1 2026.
15 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.